tiprankstipranks
Viracta Therapeutics expects cash to fund operations into Q1 of 2025
The Fly

Viracta Therapeutics expects cash to fund operations into Q1 of 2025

Cash, cash equivalents, and short-term investments totaled approximately $21.1 million as of September 30, 2024, which Viracta expects will be sufficient to fund operations late into the first quarter of 2025.

Maximize Your Portfolio with Data Driven Insights:

  • Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
  • Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App